Orphazyme predicts EU rejection after meeting with CHMP

Biotech company Orphazyme is not holding out much hope for an EU approval of its candidate arimoclomol after its meeting with the expert committee CHMP on Wednesday.
Photo: PIROSCHKA VAN DE WOUW/REUTERS / X06750
Photo: PIROSCHKA VAN DE WOUW/REUTERS / X06750
by mikkel aabenhus hemmingsen, translated by catherine brett

An indicative vote taken on Wednesday by the CHMP, an expert panel that is part of the European Medicines Agency, did not result in a majority in favor of recommending Orphazyme’s candidate arimoclomol for approval in the region. The CHMP (Committee for Medicinal Products for Human Use) was considering arimoclomol for the indication Niemann Pick type C, a rare metabolic disease also known as NPC.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading